<--- Back to Details
First PageDocument Content
Pharmacology / Bristol-Myers Squibb / Cetuximab / Bevacizumab / Pfizer / Panitumumab / FOLFIRI / KRAS / Colorectal cancer / Medicine / Chemistry / Chemotherapy regimens
Date: 2015-03-16 01:05:14
Pharmacology
Bristol-Myers Squibb
Cetuximab
Bevacizumab
Pfizer
Panitumumab
FOLFIRI
KRAS
Colorectal cancer
Medicine
Chemistry
Chemotherapy regimens

Add to Reading List

Source URL: www.pbs.gov.au

Download Document from Source Website

File Size: 700,24 KB

Share Document on Facebook

Similar Documents

Stuttgart Research Center Systems Biology (SRCSB) Systems Biology Seminar Talk „Heterogeneity and druginduced plasticity in colorectal cancer“

DocID: 1voOg - View Document

Histopathology 2007, 50, 113–130. DOI: j02549.x REVIEW Classification of colorectal cancer based on correlation of clinical, morphological and molecular features

DocID: 1vkot - View Document

TUESDAY POSTER PRESENTATION TP01 - Cancer, Clinical and Translational Proteomics MO01-001 Verification of colorectal cancer biomarker candidates in plasma/serum extracellular vesicles by targeted proteomics Takeshi Tomon

DocID: 1v6qe - View Document

License Agreement to Develop Colorectal Cancer Risk Assessment Test

DocID: 1v4r9 - View Document

UNIVERSITY HOSPITAL & CLINICS COLORECTAL CANCER IN ACADIANA 2017 PHYSICIAN STUDY Overview: Colorectal cancer is the third leading type of cancer diagnosed in the U.S. There was an estimated 135,430 cases inColorec

DocID: 1uS1a - View Document